The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn's disease: Results from the US VICTORY consortium Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal, Humanized
  • Crohn Disease
  • Gastrointestinal Agents

abstract

  • VDZ is a safe and effective treatment option for moderate-severe CD in routine practice. Clinical remission and deep remission (clinical remission and mucosal healing) can be achieved in 1/3 of individuals, and a minority of individuals require discontinuation of therapy due to adverse events.

publication date

  • August 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1038/ajg.2016.236

PubMed ID

  • 27296941

Additional Document Info

start page

  • 1147

end page

  • 55

volume

  • 111

number

  • 8